UNASSIGNED: To assess the impact of adding Bevacizumab to chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer.
UNASSIGNED: Comprehensive searches have been performed on electronic databases such as PubMed, and Google Scholar using the following terms: colorectal cancer, adenocarcinoma, Bevacizumab, chemotherapy, and monoclonal antibody.
UNASSIGNED: In the meta-analysis, 16 out of the 24 included studies were analysed. In the final analysis, incorporating Bevacizumab with chеmothеrapy demonstrated favourable outcomes for OS with a hazard ratio (HR = 0.689,95%CI: 0.51-0.83, I² = 39%, p <0.01) and for PFS with a hazard ratio (HR = 0.77 95% CI: 0.60-0.96, I² = 54%, p < 0.01). The subgroup analysis of PFS, categorised by study dеsign (prospеctivе vs rеtrospеctivе), reveals that the Hazard Ratio (HR = 0.82, 95% CI: 0.62-0.97, I² = 21%, p < 0.01) and for OS with a hazard ratio (HR = 0.73, 95% CI: 0.52-0.86, I² = 17%, p < 0.01).
UNASSIGNED: Our findings indicate that combining Bevacizumab with chemotherapy enhances clinical outcomes and results in a significant increase in PFS and OS in patients with metastatic colorectal cancer. Positive outcomes are demonstrated by a substantial 23% increase in PFS and 31% increase in OS in patients with metastatic colorectal cancer who undergo Bevacizumab in conjunction with chemotherapy.
评估在转移性结直肠癌患者化疗中加入贝伐单抗对无进展生存期(PFS)和总生存期(OS)的影响。
■已在PubMed等电子数据库上进行了全面搜索,和谷歌学者使用以下术语:结直肠癌,腺癌,贝伐单抗,化疗,和单克隆抗体。
■在荟萃分析中,对24项纳入研究中的16项进行了分析。归根结底,将贝伐单抗与chomothectuderatiy合并显示出OS的有利结果,风险比(HR=0.689,95CI:0.51-0.83,I²=39%,p<0.01)和具有危险比的PFS(HR=0.7795%CI:0.60-0.96,I²=54%,p<0.01)。PFS的亚组分析,按研究符号分类(prosp市与r市),揭示了危险比(HR=0.82,95%CI:0.62-0.97,I²=21%,p<0.01)和具有危险比的OS(HR=0.73,95%CI:0.52-0.86,I²=17%,p<0.01)。
■我们的研究结果表明,贝伐单抗联合化疗可提高转移性结直肠癌患者的临床预后,并导致PFS和OS显著增加。在接受贝伐单抗联合化疗的转移性结直肠癌患者中,PFS显着增加了23%,OS增加了31%,证明了积极的结果。